Long-term outcomes for penile cancer patients presenting with advanced N3 disease requiring a myocutaneous flap reconstruction or primary closure-a retrospective single centre study.

Background Penile cancer patients with advanced metastatic disease in the inguinal region present a therapeutic challenge. We compared the outcomes for patients with advanced inguinal node disease requiring myocutaneous flap reconstruction (MFR) against primary closure for N3 disease. Methods A retrospective comparative study of a consecutive cohort of advanced penile cancer patients with N3 disease was performed. Patient demographics, presenting symptoms, primary tumour site, stage and grade were recorded. The type of MFR used, patient outcomes and post-operative complications were recorded from an institutional database. Kaplan-Meier (KM) curves were calculated to analyse the cancer-specific survival (CSS) rates for the MFR group and compared with the no-MFR group. P values were calculated by log-rank and Chi square tests for CSS rates and complications respectively. Results Eighteen patients requiring MFR were identified; mean age 62 years. Ten (55.6%) patients had a first presentation with penile cancer and advanced nodal disease with the remaining 8 (44.4%) presenting with an inguinal recurrence having already undergone surgery. The majority (n=15) underwent a vertical rectus abdominis myocutaneous (VRAM) flap. The average length of stay was 23 days for the MFR group versus 8.5 days for the no-MFR group. The 5-year CSS was 20.9% for the MFR group and 39.8% for the no-MFR group (P<0.01). Conclusions Aggressive surgical management for patients with extensive nodal disease and flap reconstruction is feasible and aids wound management although the long-term prognosis is still poor.

[1]  R. Nigam Faculty Opinions recommendation of Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  R. Uzzo,et al.  Treatment Trends and Outcomes for Patients With Lymph Node–Positive Cancer of the Penis , 2018, JAMA oncology.

[3]  P. Spiess,et al.  Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer. , 2018, European urology focus.

[4]  J. Eidt,et al.  Outcomes after retroflexed gracilis muscle flap for vascular infections in the groin. , 2016, Journal of vascular surgery.

[5]  N. Kekre,et al.  Tensor fascia lata flap reconstruction following groin dissection: is it worthwhile? , 2011, World Journal of Urology.

[6]  S. Withey,et al.  Palliation of male genital cancers. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[7]  N. Nicolai,et al.  Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. , 2009, European urology.

[8]  A. Ornellas Management of penile cancer , 2008, Journal of surgical oncology.

[9]  C. Corbishley,et al.  Reconstructive surgery for invasive squamous carcinoma of the glans penis. , 2007, European urology.

[10]  S. Minhas,et al.  Vertical rectus abdominis flap reconstruction in patients with advanced penile squamous cell carcinoma , 2007, BJU international.

[11]  C. Corbishley,et al.  Organ‐sparing surgery for invasive penile cancer: early follow‐up data , 2004, BJU international.

[12]  S. Horenblas Lymphadenectomy for squamous cell carcinoma of the penis. Part 2: The role and technique of lymph node dissection , 2001, BJU international.

[13]  A. Ornellas,et al.  Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. , 1994, The Journal of urology.

[14]  C. Haie-meder,et al.  Penile cancer chemotherapy: twelve years' experience at Institut Gustave-Roussy. , 1993, Urology.

[15]  E. Compérat,et al.  EAU guidelines on penile cancer: 2014 update. , 2015, European urology.

[16]  L. Tanoue Cancer Statistics, 2009 , 2010 .

[17]  D M Parkin,et al.  Cancer Incidence in Five Continents. Comparability and quality of data. , 1992, IARC scientific publications.

[18]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[19]  N. Dubrawsky Cancer statistics , 2022 .